Embecta Corp.
EMBCHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeEmbecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. At a $200.5M market cap, Embecta Corp. ranks as a micro-cap company within healthcare. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Market Cap
$200.5M
Beta
1.05
P/E (TTM)
1.79
P/E (Fwd)
1.94
EPS (TTM)
$1.89
EPS (Fwd)
$1.74
ROE
—
ROA
16.8%
Cash
$184.9M
Total Debt
$1.37B
Free CF
$195.8M
52W Change
-67.7%
Annual Financials
Cash vs Debt
On the balance sheet, EMBC has $184.9M in cash with $1.37B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $195.8M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on assets of 16.8% further supports the picture of efficient asset utilization. Revenue has been relatively flat, moving from $1.13B (2022) to $1.08B (2025).
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Embecta Corp.'s trajectory.